Research programme: psoriasis therapeutic - BioLineRx
Alternative Names: BL-7020Latest Information Update: 26 Mar 2013
At a glance
- Originator BioRap; The Tel Aviv Sourasky Medical Center
- Developer BioLineRx
- Class Recombinant proteins
- Mechanism of Action Keratinocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 01 Mar 2013 Discontinued - Preclinical for Psoriasis in Israel (unspecified route)